Literature DB >> 31392150

Molecular subtypes and response to immunotherapy in bladder cancer patients.

Tilman Todenhöfer1,2, Roland Seiler3.   

Abstract

Entities:  

Year:  2019        PMID: 31392150      PMCID: PMC6642947          DOI: 10.21037/tau.2019.06.21

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN: 2223-4683


× No keyword cloud information.
  14 in total

1.  Toward a molecular pathologic classification of urothelial carcinoma.

Authors:  Gottfrid Sjödahl; Kristina Lövgren; Martin Lauss; Oliver Patschan; Sigurdur Gudjonsson; Gunilla Chebil; Mattias Aine; Pontus Eriksson; Wiking Månsson; David Lindgren; Mårten Fernö; Fredrik Liedberg; Mattias Höglund
Journal:  Am J Pathol       Date:  2013-07-01       Impact factor: 4.307

2.  A molecular taxonomy for urothelial carcinoma.

Authors:  Gottfrid Sjödahl; Martin Lauss; Kristina Lövgren; Gunilla Chebil; Sigurdur Gudjonsson; Srinivas Veerla; Oliver Patschan; Mattias Aine; Mårten Fernö; Markus Ringnér; Wiking Månsson; Fredrik Liedberg; David Lindgren; Mattias Höglund
Journal:  Clin Cancer Res       Date:  2012-05-02       Impact factor: 12.531

3.  Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.

Authors:  Roland Seiler; Hussam Al Deen Ashab; Nicholas Erho; Bas W G van Rhijn; Brian Winters; James Douglas; Kim E Van Kessel; Elisabeth E Fransen van de Putte; Matthew Sommerlad; Natalie Q Wang; Voleak Choeurng; Ewan A Gibb; Beatrix Palmer-Aronsten; Lucia L Lam; Christine Buerki; Elai Davicioni; Gottfrid Sjödahl; Jordan Kardos; Katherine A Hoadley; Seth P Lerner; David J McConkey; Woonyoung Choi; William Y Kim; Bernhard Kiss; George N Thalmann; Tilman Todenhöfer; Simon J Crabb; Scott North; Ellen C Zwarthoff; Joost L Boormans; Jonathan Wright; Marc Dall'Era; Michiel S van der Heijden; Peter C Black
Journal:  Eur Urol       Date:  2017-04-05       Impact factor: 20.096

4.  Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.

Authors:  Woonyoung Choi; Sima Porten; Seungchan Kim; Daniel Willis; Elizabeth R Plimack; Jean Hoffman-Censits; Beat Roth; Tiewei Cheng; Mai Tran; I-Ling Lee; Jonathan Melquist; Jolanta Bondaruk; Tadeusz Majewski; Shizhen Zhang; Shanna Pretzsch; Keith Baggerly; Arlene Siefker-Radtke; Bogdan Czerniak; Colin P N Dinney; David J McConkey
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

5.  Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology.

Authors:  Jeffrey S Damrauer; Katherine A Hoadley; David D Chism; Cheng Fan; Christopher J Tiganelli; Sara E Wobker; Jen Jen Yeh; Matthew I Milowsky; Gopa Iyer; Joel S Parker; William Y Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-11       Impact factor: 11.205

6.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

7.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition.

Authors:  Mark Yarchoan; Alexander Hopkins; Elizabeth M Jaffee
Journal:  N Engl J Med       Date:  2017-12-21       Impact factor: 91.245

8.  Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Authors:  A Gordon Robertson; Jaegil Kim; Hikmat Al-Ahmadie; Joaquim Bellmunt; Guangwu Guo; Andrew D Cherniack; Toshinori Hinoue; Peter W Laird; Katherine A Hoadley; Rehan Akbani; Mauro A A Castro; Ewan A Gibb; Rupa S Kanchi; Dmitry A Gordenin; Sachet A Shukla; Francisco Sanchez-Vega; Donna E Hansel; Bogdan A Czerniak; Victor E Reuter; Xiaoping Su; Benilton de Sa Carvalho; Vinicius S Chagas; Karen L Mungall; Sara Sadeghi; Chandra Sekhar Pedamallu; Yiling Lu; Leszek J Klimczak; Jiexin Zhang; Caleb Choo; Akinyemi I Ojesina; Susan Bullman; Kristen M Leraas; Tara M Lichtenberg; Catherine J Wu; Nicholaus Schultz; Gad Getz; Matthew Meyerson; Gordon B Mills; David J McConkey; John N Weinstein; David J Kwiatkowski; Seth P Lerner
Journal:  Cell       Date:  2017-10-05       Impact factor: 41.582

9.  Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification.

Authors:  Gottfrid Sjödahl; Pontus Eriksson; Fredrik Liedberg; Mattias Höglund
Journal:  J Pathol       Date:  2017-03-28       Impact factor: 7.996

10.  TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Authors:  Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962

View more
  5 in total

1.  The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications.

Authors:  Ahmet Murat Aydin; Brittany L Bunch; Matthew Beatty; Ali Hajiran; Jasreman Dhillon; Amod A Sarnaik; Shari Pilon-Thomas; Michael A Poch
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

2.  Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes.

Authors:  Zihao Chen; Guojun Liu; Guoqing Liu; Mikhail A Bolkov; Khyber Shinwari; Irina A Tuzankina; Valery A Chereshnev; Zhifeng Wang
Journal:  Hereditas       Date:  2021-01-02       Impact factor: 3.271

3.  Deconvolution of heterogeneous tumor samples using partial reference signals.

Authors:  Yufang Qin; Weiwei Zhang; Xiaoqiang Sun; Siwei Nan; Nana Wei; Hua-Jun Wu; Xiaoqi Zheng
Journal:  PLoS Comput Biol       Date:  2020-11-30       Impact factor: 4.475

4.  Practicability of clinical application of bladder cancer molecular classification and additional value of epithelial-to-mesenchymal transition: prognostic value of vimentin expression.

Authors:  João Lobo; Sara Monteiro-Reis; Catarina Guimarães-Teixeira; Paula Lopes; Isa Carneiro; Carmen Jerónimo; Rui Henrique
Journal:  J Transl Med       Date:  2020-08-05       Impact factor: 5.531

Review 5.  The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma.

Authors:  Ho Won Kang; Wun-Jae Kim; Seok Joong Yun
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.